RGNX
REGENXBIO Inc.
$13.28
+0.19 (+1.45%)
At close · Jul 2
Market Cap
$686.54M
Shares
51,697,621
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.28
Open$13.63
Day$13.17–14.25
52W$5.46–16.19
Avg vol 30d2.2M
Short int9.3M · 17.9% float · 7.0d
Short vol41%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+28% above
+
Price vs 50-day avg
+60% above
−
RSI (14)
84 · overbought
+
MACD trend
positive
◦
52-week position
73% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $8 › 200d $10 — 200d above 50d
+
Institutional flow
2 of 179 funds reported for Jun 30 · net +1.0K sh shares
−
Insider flow
Net -$857.5K over 90 days · 100% sells
−
Short interest
17.92% of float · ▲ +11.9% MoM · 7.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
179 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+678% Y/Y
+
EPS growth
+18% Y/Y
−
Free cash flow
$-126.4M
+
Balance sheet
net cash $34.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 11, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+28% above
Bullish
Price vs 50-day avg
+60% above
Bullish
RSI (14)
84 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
73% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
2 of 179 funds reported for Jun 30 · net +1.0K sh shares
Insider flow
Distributing
Net -$857.5K over 90 days · 100% sells
Short interest
Rising
17.92% of float · ▲ +11.9% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
179 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $5
Now $13 · 73%
52-wk high $16
vs 200-day avg +28%
vs 50-day avg +60%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGNX
this stock
REGENXBIO Inc.
|
$686.54M | -7.8% | +24.0% | — | 17.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGNX | +29.7% | +98.5% | -11.5% | +10.9% | -7.8% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +28.3% | +99.8% | -19.5% | +11.1% | -17.0% |